Eastwood's official statement on rumors related to some diabetes products that claim to 'cure type 1 diabetes'
Between 1995 and 1997, our company acquired several technologies related to improving 'metabolic syndrome' jointly developed by the University of Calgary in Canada and Yale University in the United States. Afterwards, our company obtained approval from the Canadian Food and Drug Administration and the Chinese government based on this technology, and currently produces and sells approximately 150 products in various fields, including metabolic syndrome.
At the time, the research team that provided us with the metabolic syndrome technology was a diabetes authority who had been nominated for the American Diabetes Association and the Nobel Prize several times. These were world leaders in the field of diabetes, including . The Julia McFarlan Institute at the University of Calgary and Yale University School of Medicine, where the study was conducted, are among the most internationally renowned type 1 diabetes research institutions.
The technology acquired at that time was various herbal complex formulas. Among them, he said he would like our company to take the lead in commercializing a groundbreaking herbal formula that says, "Type 1 diabetes can be completely cured if used for about two years."
For that technology, $40 million in support from the Canadian government had already been invested, animal testing and basic human testing were completed, and intellectual property rights were protected.
However, if you make an announcement under the name of the University of Calgary or Yale University, you will receive enormous political attacks from diabetes specialists and pharmaceutical companies who thoroughly believe that ‘Type 1 diabetes will never be cured,’ and do not specify a specific active ingredient (Active Ingredient). Because it is an herbal formula, they are concerned that it will receive severe attacks from mainstream academia, which only focuses on specific active substances.
In particular, it would be difficult for our university, which receives a lot of support from pharmaceutical companies, so we requested that our company, which is not affiliated with a university, find an appropriate way to disclose and commercialize the product.
Then, when I was concerned, ‘Will our company also be attacked?’, they insisted for a long time that I should give it a try, saying that they would guarantee the scientific results and results with documentation.
I was young at the time, and I felt that I could overcome many difficulties if I fought, so I gathered my courage and started commercializing this project. We invested approximately 200 billion won in research and development funds into this and other technologies, and completed the development and licensing process for approximately 150 products. (SuperEleotin.com)
However, when we tried to commercialize and sell type 1 diabetes, there was a huge backlash from vested interests. The world's largest pharmaceutical company tried to persuade us to sell the technology to them, and even threatened to bankrupt our company using various methods if we did not sell it. There were various pressures.
In fact, in the case of Dr. Jiwon Yoon's team, one of the research results (another technology unrelated to our product) published before his death was unfairly criticized as 'the researchers must have lied about the original results because re-experiments at other institutions did not produce the same results.' You were falsely accused and suffered great disgrace. Even now, if you search, you can find such stories.
However, I saw with my own eyes that the results actually came out at the original experiment site where the results were suspected of being faked. Perhaps Dr. Yoon published the treatment technology he published in his thesis (it is a separate technology from the products we sell) without disclosing some critically important know-how, but then someone else claimed it was the same experiment and revealed that important know-how. I assume that the experiment was conducted unnecessarily and the same results were not obtained (of course). (Even for our company, we do not write down commercially important know-how in patents or product labels. We tried what is on our product labels and patents, and some may criticize our company for not being effective, but we do not write down this commercially important know-how. Not disclosing how is a common occurrence in the scientific community, especially in the pharmaceutical-bio community.) I personally believe that this has a political background.
I was very concerned about the political attacks that our company could face if we produced and sold 'type 1' diabetes products. Therefore, we discussed with the authorities for a long time at the time of product approval.
When applying for a license, it was originally necessary to clearly distinguish whether the product's intended use was for type 1 diabetes or type 2 diabetes, but we agreed with the licensing authorities to deliberately not distinguish between them and just use it for 'blood sugar health.' While obtaining approval in a broader category (No. 1 + No. 2), we agreed to avoid the expression “cure” and use the broad expression “Promote Healthy Blood Sugar Level” to help normalize blood sugar levels. Type 1 diabetics may interpret this as saying, “Type 1 diabetes can be completely cured,” but our company decided to protect itself with a kind of ‘strategic ambiguity’ by not specifically making such claims, and thus licensed. Acquired.
And our company focused on the type 2 diabetes market. There was no advertising or marketing activity regarding the type 1 diabetes market.
However, many desperate parents of type 1 diabetics started using our product even though we did not advertise it.
In many cases, the results are very good (the results will be collected and reported separately later), and although it is nice to have good results, people still have to continue to use insulin for a long time, but they are happy that they are 'cured' and stop taking insulin arbitrarily. There have been quite a few cases. It's a very dangerous thing. So, we designated a specialist and created educational materials that strictly inject the message that you should only stop taking insulin based on that person's prescription, and that you should not stop taking insulin on your own, thinking that your blood sugar has normalized after using our product and the results are good. We still repeat such training from time to time. However, we still have not targeted the type 1 diabetes market. This is because the returns from the market are much smaller than the risks.
However, several Type 1 patients' videos of their experience with our product began to circulate on the Internet, word of mouth spread even more, dozens of patients' families began to gather in online cafes, and the media was also recently caught and began reporting. I heard.
However, if a media organization that is not familiar with the content reports it inaccurately, unfavorable distortions may occur, so we are officially stating our position here.
First, we do not claim that our products have any therapeutic or preventive effect on any disease other than the individual effects permitted by the Canadian Food and Drug Administration for individual products. We do not claim to cure type 1 diabetes. Individual users may infer that the license we received includes the statement that 'type 1 diabetes is cured', but we make it clear that we are not making such a claim. And, we do not point out that such consumer inferences are inaccurate. Although we cannot provide all commercial know-how, consumers and doctors can make their own decisions based on the data and experiences we disclose.
We have no intention of disclosing the mechanism of action, the warranty written by the two diabetes academic leaders who created this formula at the university, the specific formula, and the overall clinical results to the public yet.
Data and samples may be provided purely for the purpose of qualified researchers.
We will continue to update related information in our Facebook group 'Eleotin Natural Health University'.
September 20, 2021
Eastwood Bio-Medical Research Inc.